Key result
A bibliometric analysis of 499 articles from 2000 to 2024 identified a marked increase in studies on neuromuscular monitoring and reversal agents, with the USA, China, and France leading.
Why the study?
The study was conducted to analyze global research trends, citation impact, and scientific collaborations in the field of neuromuscular blockers and their antagonists between 2000 and 2024.
This bibliometric analysis highlights a shift in neuromuscular blocker research over the past two decades from pharmacokinetics to safety, monitoring, and reversal agents like sugammadex.
Answers are grounded in this paper and cite their sources.
Bibliometric mapping of NMBA trends; leaves open targeted trials to address identified gaps.
(1) Background: The aim of this bibliometric study is to analyze global research trends, citation impact, and scientific collaborations in the field of neuromuscular blockers (NMBAs) and their antagonists between 2000 and 2024. (2) Methods: Data were retrieved from the Web of Science Core Collection (WoSCC) using Boolean search strategies. Bibliometric analyses were conducted using R bibliometrix, VOSviewer, and CiteSpace software to visualize collaboration networks, keyword trends, and citation bursts. (3) Results: A total of 499 articles were analyzed, with the United States of America (USA), China, and South Korea leading in productivity, while France had the highest citation impact. Influential authors included Mertes PM and Fuchs-Buder T. Emerging topics such as sugammadex, sevoflurane, and neuromuscular monitoring were identified, reflecting a shift from pharmacokinetic studies to safety and monitoring strategies. (4) Conclusions: The findings indicate a marked increase in studies on neuromuscular monitoring and reversal agents, such as sugammadex, over the past two decades. The USA, France, and China emerged as the most contributory countries in NMBAs research, with their extensive international collaborations playing a pivotal role in shaping scientific progress. Highly influential studies have predominantly focused on NMBA pharmacokinetics, safety, anaphylaxis risks, and the clinical benefits of sugammadex, underscoring its critical role in reducing residual neuromuscular blockade (rNMB) and enhancing patient safety.
No takes yet. Share an insight, caveat, or question.
Evran et al. (2025) studied Neuromuscular blockers and antagonists (n=499). Neuromuscular blockers and antagonists research was evaluated on Global research trends, citation impact, and scientific collaborations. A bibliometric analysis of 499 articles from 2000 to 2024 identified a marked increase in studies on neuromuscular monitoring and reversal agents, with the USA, China, and France leading.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: